Stock Updates

A look at a High Market Cap Stock: Regeneron Pharmaceuticals, Inc., REGN

Regeneron Pharmaceuticals, Inc., REGN is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Regeneron Pharmaceuticals, Inc., REGN  has a market cap of 44394.46. Since its IPO date on the 4/2/1991, Regeneron Pharmaceuticals, Inc., REGN performance year to date is -22.44%. Today Regeneron Pharmaceuticals, Inc., REGN has gained -0.44%, with a current price of 419.2.

Ownership of the company is 0.50% for insider ownership while institutional ownership is 71.50%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 13.70%, with return on investment at 16.00%.

In terms of debt levels and profit levels, Regeneron Pharmaceuticals, Inc., REGN is seeing a long-term debt/equity of 0.1. While Total debt/equity is 0.1. With a profit margin of 16.40%, this is combined with a gross margin of 90.50%, and operating margin of 28.90%. Regeneron Pharmaceuticals, Inc. ability to meet debt levels, with a current ratio of 3.4, while the quick ratio is 3.1.

For the last year Regeneron Pharmaceuticals, Inc., REGN has seen a EPS growth of 85.10%. A performance for the year of -27.29%. The 52-week high is -29.26%, and the 52-week low is 27.38%. The average volume for Regeneron Pharmaceuticals, Inc., REGN is 217002.

With a target price of 469.55, can Regeneron Pharmaceuticals, Inc., REGN reach this target? Looking at the value indicators of Regeneron Pharmaceuticals, Inc., REGN. Regeneron Pharmaceuticals, Inc. has a P/E of 66.86 and a forward P/E of 28.76. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.5. Regeneron Pharmaceuticals, Inc. also has a P/S and a P/B of 10.01 and 11.66 respectively. For P/cash, Regeneron Pharmaceuticals, Inc. has a value of 52.28, while it is 44.59 for P/free cash flow.

At the current price of 419.2, Regeneron Pharmaceuticals, Inc. has a dividend yield of *TBA. We see a return on equity of 20.70%.

Looking more long-term Regeneron Pharmaceuticals, Inc., is projected to get an EPS growth for the next five years of 19.09%. In the short-term an EPS growth of 34.43% in the next year is forecasted. This is after a EPS growth of 85.10% for this year and for the last five years a 44.90% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment